PMI locally produces Myanmar’s first semaglutide

News Image

  • PMI locally produces Myanmar’s first semaglutide

AA Medical Products Ltd announced on 14 February the successful production of semaglutide (Seglupac), Myanmar’s first locally manufactured treatment for diabetes and obesity.
A hybrid webinar was held on 8 February at the Melia Hotel in Yangon to commemorate this first production by Pacific Medical Industries (PMI), one of Myanmar’s leading pharmaceutical manufacturers.
The announcement stated that PMI has successfully produced this world-class diabetes treatment locally, meeting international standards. The product aims to provide patients with an affordable alternative that offers the same quality as expensive imported medications.
At the ceremony, Co-founder & Group Vice-Chairwoman Dr Saw Nay Nwe delivered the opening remarks and introduced the company’s advanced new product, Seglupac.
Following this, Mr Deven, CEO of PMI, presented the topic ‘Control, Comfort, Confidence’, regarding the entire production process, starting from the selection of high-grade API raw materials for the manufacturing of Seglupac. — MT/ZN

gnlm